NovAccel

NovAccel is a Tsuchiura, Ibaraki-based Japanese startup developing a compact superconducting accelerator (RiSA) for manufacturing medical radioisotopes, specifically Actinium-225 (Ac-225) used in targeted alpha therapy (TAT) for cancer treatment. The company is building a domestic supply chain for Ac-225 to address global shortages constraining next-generation oncology research, including securing Ra-226 feedstock through participation in the IAEA Global Radium Initiative. It aims to complete its accelerator manufacturing facility by October 2026 and begin sample shipments in Q4 2026.

  • Seed
  • Biotechnology
  • Healthtech
  • Medtech
  • Healthcare & Life Sciences

1

Round

1

Industry

4

Tags

Nov 17, 2026

Latest raise

Funding activity · 1 round

Raise timeline

  1. Nov 17, 2026

    JPY 290M

    Seed

    • XTech Ventures
    • Inoue Co., Ltd. (株式会社イノウエ)

    NovAccel Raises ¥290M Seed to Build Domestic Ac-225 Supply Chain

    NovAccel Secures ¥290 Million in Seed Funding NovAccel, a Japanese startup based in Tsuchiura, Ibaraki, has raised ¥290 million in Seed funding. The round was…

    Read article

Pricing

Research NovAccel — then scale the playbook

Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.

Enterprise

Custom pricing for unlimited scale. Let's talk.

Contact sales

Growth plan

For individuals and small teams getting started with AI buyer intelligence.

$149

/month

Features

  • Access to core AI adoption signals
  • 3–5 curated slices per week
  • 30–60 companies / week
  • AI Adoption Score
  • Deal-ready insights (why + pitch angle)
  • Basic filters (recency, slice, score)
  • CSV export
Most popular

Pro plan

For outbound teams and agencies that need more coverage and faster signal cadence.

$249

/month

Features

  • Everything in Growth, plus:
  • Full access to all slices
  • 60–120 companies / week
  • Higher-frequency signal updates
  • Priority / early signals (before Growth)
  • Advanced filters (industry, size, use case)
  • Deeper company insights
  • Faster export + bulk workflows

Act on this raise

See if NovAccel is moving on AI

Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.

© 2026 VeilStrat. All rights reserved.All systems operational